Evidence map›Paper›PMID 29579216›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2019

Acinetobacter baumannii Resistance Trends in Children in the United States, 1999-2012.

Latania K Logan, Sumanth Gandra, Anna Trett, Robert A Weinstein, Ramanan Laxminarayan

Abstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prevalence and risk factors ofF1000Research · 2024
    Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Epidemiology and antimicrobial resistance trends ofFrontiers in public health · 2023
    Article
  17. Characterization ofBiology · 2022
    Article
  18. Deletion of a previously uncharacterized lipoprotein lirL confers resistance to an inhibitor of type II signal peptidase inProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  19. Decreasing incidence ofInfection control and hospital epidemiology · 2022
    Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Latania K LoganDepartment of Pediatrics, Division of Infectious Diseases, Rush Medical College, Rush University Medical Center, Chicago, Illinois.
Sumanth GandraCenter for Disease Dynamics, Economics & Policy, Washington, DC.
Anna TrettCenter for Disease Dynamics, Economics & Policy, Washington, DC.
Robert A WeinsteinDepartment of Internal Medicine, Division of Infectious Diseases, Rush Medical College, Rush University Medical Center, Chicago, Illinois.
Ramanan LaxminarayanCenter for Disease Dynamics, Economics & Policy, Washington, DC.

Funding

The Epidemiology of Multi-Drug Resistant Enterobacteriaceae Infections in ChildreK08AI112506 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI LOGAN, LATANIA K. · 2014 to 2018
$916k
NIAID NIH HHS K08 AI112506
6 · The paper itself

Abstract

backgroundAcinetobacter baumannii is a common cause of healthcare-associated infections. Carbapenem-resistant (CR) A baumannii is a significant threat globally. We used a large reference laboratory database to study the epidemiology of A baumannii in children in the United States.

methodsAntimicrobial susceptibility data from The Surveillance Network were used to phenotypically identify antibiotic resistance in A baumannii isolates in children 1-17 years of age between January 1999 and July 2012. Logistic regression analysis was used to calculate trends in the prevalence of antibiotic resistance in A baumannii. Isolates from infants (<1 year old) were excluded.

resultsThe crude proportion of cephalosporin-resistant (CephR) A baumannii increased from 13.2% in 1999 to 23.4% in 2012 with a peak of 32.5% in 2008, and the proportion of CR A baumannii increased from 0.6% in 1999 to 6.1% in 2012 with a peak of 12.7% in 2008. From 1999 to 2012, the proportion of CephR and CR A baumannii increased each year by 3% and 8%, respectively (CephR odds ratio [OR] = 1.03, 95% confidence interval [CI], 1.01-1.04; CR OR = 1.08, 95% CI, 1.05-1.12); however, after 2008, a significant decrease in trend was observed (CephR OR = 0.78, 95% CI, 0.71-0.87; CR OR = 0.73, 95% CI, 0.62-0.86), but resistance remained higher than baseline (1999).

conclusionsOverall, between 1999 and 2012, CephR and CR A baumannii isolates increased in children; however, a decreasing trend was observed after 2008.There is a need for ongoing surveillance of A baumannii infections and continued assessment of effective prevention strategies in vulnerable populations.

Indexed as

Drug Resistance, Multiple, BacterialAcinetobacter baumanniiAcinetobacter InfectionsAdolescentAnti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaeCarbapenemsCephalosporinsChildChild, PreschoolCross InfectionDatabases, FactualFemaleHumansInfantLogistic ModelsAnti-Bacterial AgentsCarbapenemsCephalosporinsAcinetobacter baumanniicarbapenemschilddrug resistanceepidemiology

Identifiers

PMID29579216
PMCPMC6510944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.